Dr. David A. Bond, MD
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Medical school
- Indiana University School of Medicine (2012)
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 168
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Medical school: Indiana University School of Medicine
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
OH license 35.124243
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Ohio State University State Health System Columbus, OH
Medical groups
- Osu Internal Medicine LLC (1,161 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 168
- Services billed
- 682
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 157 | 41 |
| Established patient office or other outpatient visit, 40-54 minutes | 100 | 45 |
| Established patient office or other outpatient visit, 30-39 minutes | 67 | 50 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 21 | 21 |
| Hospital discharge day management, more than 30 minutes | 17 | 17 |
| Established patient office or other outpatient visit, 20-29 minutes | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Brukinsa (zanubrutinib) | 52 |
| Eliquis (apixaban) Other prescribers in Columbus, OH | 22 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Columbus, OH | 15 |
| Allopurinol Other prescribers in Columbus, OH | 12 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 3 payments worth $1,859 in total to this clinician.
| Incyte Corporation | $1,650 |
|---|---|
| AstraZeneca Pharmaceuticals LP | $135 |
| Genentech USA, Inc. | $74.16 |
| Consulting Fee | $1,650 |
|---|---|
| Food and Beverage | $209 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Incyte Corporation May 29, 2025 | Consulting Fee | $1,650 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 10 industry-funded studies in 2025, from 8 companies. The companies reported $648,280 in research payments for these studies, mostly to the institutions running them.
- Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies
Beone Medicines Ltd. · Active, not recruiting · NCT04277637 - A Phase Ib Trial of Tafasitamab and Lenalidomide Followed by Tafasitamab, Lenalidomide, and ICE as Salvage Therapy for Transplant Eligible Patientswith Relapsed/ Refractory Diffuse Large B Cell Lymphoma
Incyte Corporation - Study name not reported
Adaptive Biotechnologies Corporation - A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
Beone Medicines Ltd. · Recruiting · NCT06742996 - Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
Novartis Pharmaceuticals Corporation - A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
Genmab A/s - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
Celgene Corporation - Expanded Access Protocol (EAP) of subjects receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release
E.r. Squibb & Sons, L.l.c. - Long Term Follow Up of Patients Exposed to Lentiviral Based CD19 Directed CAR T Cell Therapy
Novartis Pharmaceuticals Corporation - Tafasitamab, lenalidomide and venetoclax for relapsed/refractory mantle cell lymphoma: A phase 2 study with safety run-in
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.